In July the US Court of Appeals for the Federal Circuit sought to clarify the rules on the ‘patent dance’, but with confusion reigning there are likely to be more twists and turns to come, as LSIPR finds out.
“I’ve given up predicting what the court is going to do,” says one lawyer commenting on the latest ‘patent dance’ ruling.
Although not often associated with high-stakes litigation, the term ‘dance’ has recently become widely used in the US biopharmaceutical industry. In July one of the biggest disputes surrounding the patent dance was resolved when the US Court of Appeals for the Federal Circuit ruled in Amgen v Sandoz.
But several months later, there seems to be plenty of confusion around key aspects of the ruling.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
Biosimilar, Barnes & Thornburg, BPCIA, patent dance, FDA, Amgen, en banc review, US Court of Appeals for the Federal Circuit, Sandoz